ea0016oc3.9 | Diabetes and obesity | ECE2008
Sapunar Jorge
, Munoz Sergio
, Jimenez Marcela
, Ortiz Eugenia
Nissens meta-analysis concluded that the use of Rosiglitazone (RSG) was associated with a significant increase in the risk of myocardial infarction. However, none of the analyzed studies took into account the cardiovascular events as primary outcomes, neither were controlled by cardiovascular risk factors.Objectives: 1. To know if there is an association between RSG myocardial infarction OR and the magnitude of the difference in baseline serum lipi...